Evan Klein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Evan Klein has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Alan Todd Blank
Department of Orthopedic Surgery, Section of Orthopedic Oncology, Rush University Medical Center, Chicago, Illinois
2 shared publications - Conor M. Jones
Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, Illinois
2 shared publications - Linus Lee
Department of Orthopaedic Surgery, MedStar Georgetown University Hospital, Washington, DC
2 shared publications - Matthew W. Colman
Department of Orthopedic Surgery, Rush University Medical Center, Chicago, IL, USA
2 shared publications - Michael Fice
Department of Orthopaedic Surgery, University of California, Los Angeles, CA, USA
2 shared publications - Neil Buac
Department of Orthopedic Surgery, Section of Orthopedic Oncology, Rush University Medical Center, Chicago, IL, USA
2 shared publications
Latest Publications
- 7 March 2024
- Published by Elsevier in Surgical Oncology
- Vol. 57, 102057
Development and external validation of a machine learning model for prediction of survival in extremity leiomyosarcoma
- 7 March 2024
- Published by Elsevier in Surgical Oncology
- Vol. 57, 102057
Development and external validation of a machine learning model for prediction of survival in extremity leiomyosarcoma
- 1 September 2023
- Published by Springer Nature in MUSCULOSKELETAL SURGERY
- Vol. 108 (1) , 77-86
Development and external validation of a machine learning model for prediction of survival in undifferentiated pleomorphic sarcoma
Purpose Machine learning (ML) algorithms to predict cancer survival have recently been reported for a number of sarcoma subtypes, but none have investigated undifferentiated pleomorphic sarcoma (UPS). ML is a powerful tool that has the potential to better prognosticate UPS. Methods The Surveillance, Epidemiology, and End Results (SEER) database was queried for cases of histologically confirmed undifferentiated pleomorphic sarcoma (UPS) (n = 665). Patient, tumor, and treatment characteristics were recorded, and ML models were developed to predict 1-, 3-, and 5-year survival. The best performing ML model was externally validated using an institutional cohort of UPS patients (n = 151). Results All ML models performed best at the 1-year time point and worst at the 5-year time point. On internal validation within the SEER cohort, the best models had c-statistics of 0.67–0.69 at the 5-year time point. The Multi-Layer Perceptron Neural Network (MLP) model was the best performing model and used for external validation. Similarly, the MLP model performed best at 1-year and worst at 5-year on external validation with c-statistics of 0.85 and 0.81, respectively. The MLP model was well calibrated on external validation. The MLP model has been made publicly available at https://rachar.shinyapps.io/ups_app/. Conclusion Machine learning models perform well for survival prediction in UPS, though this sarcoma subtype may be more difficult to prognosticate than other subtypes. Future studies are needed to further validate the machine learning approach for UPS prognostication.
- 1 September 2023
- Published by Springer Nature in MUSCULOSKELETAL SURGERY
- Vol. 108 (1) , 77-86
Development and external validation of a machine learning model for prediction of survival in undifferentiated pleomorphic sarcoma
Purpose Machine learning (ML) algorithms to predict cancer survival have recently been reported for a number of sarcoma subtypes, but none have investigated undifferentiated pleomorphic sarcoma (UPS). ML is a powerful tool that has the potential to better prognosticate UPS. Methods The Surveillance, Epidemiology, and End Results (SEER) database was queried for cases of histologically confirmed undifferentiated pleomorphic sarcoma (UPS) (n = 665). Patient, tumor, and treatment characteristics were recorded, and ML models were developed to predict 1-, 3-, and 5-year survival. The best performing ML model was externally validated using an institutional cohort of UPS patients (n = 151). Results All ML models performed best at the 1-year time point and worst at the 5-year time point. On internal validation within the SEER cohort, the best models had c-statistics of 0.67–0.69 at the 5-year time point. The Multi-Layer Perceptron Neural Network (MLP) model was the best performing model and used for external validation. Similarly, the MLP model performed best at 1-year and worst at 5-year on external validation with c-statistics of 0.85 and 0.81, respectively. The MLP model was well calibrated on external validation. The MLP model has been made publicly available at https://rachar.shinyapps.io/ups_app/. Conclusion Machine learning models perform well for survival prediction in UPS, though this sarcoma subtype may be more difficult to prognosticate than other subtypes. Future studies are needed to further validate the machine learning approach for UPS prognostication.